For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...
Morning Overview on MSN
Disabling NFIL3 via CRISPR kept engineered CAR T-cells from hitting exhaustion, prolonging tumor control in animal models
Researchers at Columbia University’s Sadelain lab and University Hospital Tubingen used CRISPR gene editing to knock out the ...
With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 27, research ...
News Nation on MSN
Scientists achieve most precise human embryo DNA edit to date
The breakthrough could one day allow doctors to repair disease-causing mutations in embryos.
Utah State University scientists recently unveiled a new type of CRISPR biotechnology with the ability to selectively target ...
Researchers relied on a newer gene-editing technique that may make it possible to engineer embryos, a prospect that has long ...
Millions of older adults have tiny brain hemorrhages called cerebral microbleeds, which are strongly associated with dementia ...
View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.
Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...
Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results